Clinical Efficacy of a Combination of Thymopentin and Antituberculosis Drugs in Treating Drug-Resistant Pulmonary Tuberculosis: Meta Analysis

References

• WHO. Global tuberculosis report 2020; 2020.
   Google Scholar
• Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57(6):2003300. doi:10.1183/13993003.03300-2020
   PubMed Web of Science ®Google Scholar
• Cağatay T, Kiran B, Yurt S, Gülbaran Z, Kosar F, Cağatay P. Levels of tumour necrosis factor-alpha and IL-1alpha in newly diagnosed and multidrug resistant tuberculosis. Respirology. 2005;10(3):290–294. doi:10.1111/j.1440-1843.2005.00711.x
   PubMed Web of Science ®Google Scholar
• Shahemabadi AS, Hosseini AZ, Shaghsempour S, Masjedi MR, Rayani M, Pouramiri M. Evaluation of T cell immune responses in multi-drug-resistant tuberculosis (MDR-TB) patients to mycobacterium tuberculosis total lipid antigens. Clin Exp Immunol. 2007;149(2):285–294. doi:10.1111/j.1365-2249.2007.03406.x
   PubMed Web of Science ®Google Scholar
• Sada-Ovalle I, Torre-Bouscoulet L, Valdez-Vázquez R, Lascurain R. In vitro cytotoxicity of CD8+ T cells in multi-drug-resistant tuberculosis. A preliminary report. Respirology. 2009;14(4):574–578. doi:10.1111/j.1440-1843.2008.01478.x
   PubMed Web of Science ®Google Scholar
• Yang Y, Tang SJ, Zhang Q, et al. The changes and the significance of cellular immune function in peripheral blood of patients with multidrug-resistant and extensively drug-resistant pulmonary tuberculosis. Chin J Tuberc Respir Dis. 2011;34(2):109–113. Chinese.
   Google Scholar
• Barnes PF. Immunotherapy for tuberculosis: wave of the future or tilting at windmills? Am J Respir Crit Care Med. 2003;168(2):142–143. doi:10.1164/rccm.2305001
   PubMed Web of Science ®Google Scholar
• Fan L. The research progress of immunotherapy in multidrug-resistant tuberculosis. Chin J Antituberc. 2015;37(11):1144–1149. Chinese.
   Google Scholar
• Cao Q, Gao X, Lin Y, et al. Thymopentin ameliorates dextran sulfate sodium-induced colitis by triggering the production of IL-22 in both innate and adaptive lymphocytes. Theranostics. 2019;9(25):7490–7505. doi:10.7150/thno.35015
   PubMed Web of Science ®Google Scholar
• Huang GJ, Gao Y, Tang XL, Gao X, Bai LQ. Efficacy and safety of thymopentin in adjuvant treatment of retreatment positive pulmonary tuberculosis: aMeta-analysis. Chin J Antituberc. 2020;42(06):570–577.
   Google Scholar
• Maimati A, Yakun K. Clinical evaluation of thymus pentapeptide combined with conventional anti-tuberculosis drugs in the treatment of drug-resistant tuberculosis. World Latest Med Inf. 2017;17(75):97.
   Google Scholar
• Chen W. Effect of thymus pentapeptide in adjuvant treatment of multidrug resistant pulmonary tuberculosis and its effect on immune function. J Med Theory Pract. 2021;34(10):1679–1680.
   Google Scholar
• Chen Y, Qiao XX. Adjuvant treatment of thymopentin for drug resistance senile cavitary tuberculosis. Anhui Med J. 2014;35(3):353–355.
   Google Scholar
• Guan H. Effect of thymus pentapeptide on multi-drug resistant tuberculosis. J Mod Med Health. 2008;8:1171.
   Google Scholar
• He MC, Wang CC. Study on the effect of thymus pentapeptide combined with conventional anti-tuberculosis drugs in the treatment of drug-resistant tuberculosis. Contemp Med Sympo. 2020;18(10):158–159.
   Google Scholar
• Ji MH. Clinical observation of thymus pentapeptide in adjuvant treatment of senile cavity-resistant pulmonary tuberculosis. Chin J Mod Drug Applicat. 2015;9(022):104–105.
   Google Scholar
• Kang GN, Dang P, Hou LL. Clinical effect of thymopentin combined with antituberculosis drugs on multidrug-resistance pulmonary tuberculosis patients. Clin Res Pract. 2020;5(05):39–40.
   Google Scholar
• Li J. Effects of thymopentin combined with conventional anti-tuberculosis drugs in treatment of patients with multidrug-resistant tuberculosis. Med J Chin People’s Health. 2021;33(03):6–7+10.
   Google Scholar
• Li G. Clinical observation of thymus pentapeptide in adjuvant treatment of senile cavity-resistant pulmonary tuberculosis. Curr Med Sci. 2017;23(06):113–114. Article in Chinese.
   Google Scholar
• Li HL. Efficacy of immunopotentiator thymopentin combined with conventional antituberculosis drugs in the treatment of patients with drug-resistant tuberculosis. Guide Chin Med. 2020;18(29):71–72. Article in Chinese.
   Google Scholar
• Li ZG, Du SB, Huang J, Cheng PJ, Gong HB, Yang YS. Clinical efficacy of thymopoietin combined with routine anti-tuberculosis drugs in treating drug-resistant pulmonary tuberculosis in 33 cases. Chin Pharm. 2013;22(19):95–96. Article in Chinese.
   Google Scholar
• Liu M, Zhang QL, Yu H, Meng WM. Effect of thymopentin on patients with multi-drug-resistant tuberculosis. Chin J Mod Med. 2014;24(25):87–89. Article in Chinese.
   Google Scholar
• Liu LT, Cao L. Efficacy of thymus pentapeptide combined with conventional anti-tuberculosis drugs in the treatment of drug-resistant tuberculosis patients. J Med Theory Pract. 2018;31(11):1612–1613. Article in Chinese.
   Google Scholar
• Liu SF, Zhao L, Xue J, et al. Effect of thymopentin in the adjunctive therapy of multi-drug resistant tuberculosis and its influence on immune function. J Clin Pulm Med. 2016;21(07):1279–1282. Article in Chinese.
   Google Scholar
• Mao FL, Cui YY, Zhao CY. Clinical effect of thymopentin combined with quadruple antituberculosis regimen in the treatment of drug-resistant tuberculosis. Clin Res Pract. 2020;5(27):45–47. Article in Chinese.
   Google Scholar
• Ouyang B. Observation on the effect of thymopentin in the treatment of drug-resistant tuberculosis patients and its effect on immune function and serum inflammatory factors. Chin Commun Doctors. 2019;35(14):44–45. Article in Chinese.
   Google Scholar
• Qi M, Meng YJ, Zang K. Thymus pentapeptide adjuvant treatment of 32 cases of multi-drug resistant tuberculosis. Chin J Pract Med. 2007;34(2):89. Article in Chinese.
   Google Scholar
• Wang Z. Effect of thymus pentapeptide on sputum negative rate and focal absorption rate in patients with drug-resistant tuberculosis. Heilongjiang Med J. 2021;34(01):92–94. Article in Chinese.
   Google Scholar
• Yang T. Efficacy of thymus pentapeptide combined with conventional anti-tuberculosis drugs in the treatment of drug-resistant tuberculosis patients. Mod Diagnosis Treat. 2019;30(21):3760–3761+3887. Article in Chinese.
   Google Scholar
• Yu X. Efficacy evaluation of injection thymic pentapeptide combined with 3HRZE/6HRE regimen in the treatment of drug-resistant pulmonary tuberculosis. Inner Mongolia Med J. 2020;52(06):664–665. Article in Chinese.
   Google Scholar
• Yu RM, Gao Y, Yan TH. Clinical efficacy of thymopoietin combined with the conventional anti tuberculosis drugs in the treatment of drug resistant tuberculosis. Chin Health Stand Manage. 2016;7(20):139–141. Article in Chinese.
   Google Scholar
• Zhang XN, Wang YB, Shi YG, Han XH. Effect of thymus pentapeptide in adjuvant treatment of drug-resistant bacterial positive pulmonary tuberculosis. Chin J Postgraduat Med. 2011;01:47–49. Article in Chinese.
   Google Scholar
• Zou P, Chen L, Zhu TJ, Peng SL, Pan HL, Xia M. Effect of thymopentin on adjuvant treatment of drug resistant tuberculosis patients and its effect on immune function and inflammatory factors. Chin J Difficult Complicat Cases. 2017;16(12):1217–1220. Article in Chinese.
   Google Scholar
• Dorhoi A, Reece ST, Kaufmann SH. For better or for worse: the immune response against mycobacterium tuberculosis balances pathology and protection. Immunol Rev. 2011;240(1):235–251. doi:10.1111/j.1600-065X.2010.00994.x
   PubMed Web of Science ®Google Scholar
• de la Barrera S, Aleman M, Musella R, et al. IL-10 down-regulates costimulatory molecules on mycobacterium tuberculosis-pulsed macrophages and impairs the lytic activity of CD4+ and CD8+ CTL in tuberculosis patients. Clin Exp Immunol. 2004;138(1):128–138. doi:10.1111/j.1365-2249.2004.02577.x
   PubMed Web of Science ®Google Scholar
• Wu YE, Zhang SW, Peng WG, et al. Changes in lymphocyte subsets in the peripheral blood of patients with active pulmonary tuberculosis. J Int Med Res. 2009;37(6):1742–1749. doi:10.1177/147323000903700610
   PubMed Web of Science ®Google Scholar
• Carpenter SM, Nunes-Alves C, Booty MG, Way SS, Behar SM. A higher activation threshold of memory CD8+ T cells has a fitness cost that is modified by TCR affinity during tuberculosis. PLoS Pathog. 2016;12(1):e1005380. doi:10.1371/journal.ppat.1005380
   PubMed Web of Science ®Google Scholar
• Ndishimye P, Zakham F, Musanabaganwa C, et al. CD4+ regulatory T cells and CD4+ activated T cells in new active and relapse tuberculosis. Cell Mol Biol. 2019;65(8):18–22. doi:10.14715/cmb/2019.65.8.4
   PubMed Web of Science ®Google Scholar
• Zhang XN, Ji XL, Wang Y. Effect of thymus pentapeptide in the adjuvant treatment of sputum smear positive tuberculosis. Clin Med China. 2009;9:966–968. Article in Chinese.
   Google Scholar
• Wang J, Ren RH, Li XL, Zhang CY. Therapeutic effects of thymopetidum on pulmonary tuberculosis complicated by diabetes mellitus. Hebei Med J. 2016;38(15):2283–2285. Article in Chinese.
   Google Scholar